Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins.

Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GN, Bacus SS.

Br J Cancer. 2004 Sep 13;91(6):1190-4.

PMID:
15305194
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.

Exp Cell Res. 2005 Apr 1;304(2):604-19. Epub 2005 Jan 21.

PMID:
15748904
[PubMed - indexed for MEDLINE]
3.

Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.

Sassen A, Diermeier-Daucher S, Sieben M, Ortmann O, Hofstaedter F, Schwarz S, Brockhoff G.

Breast Cancer Res. 2009;11(4):R50. doi: 10.1186/bcr2339. Epub 2009 Jul 22.

PMID:
19624808
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.

Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.

Breast Cancer Res. 2007;9(4):R50.

PMID:
17686159
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

[Breast cancer--known receptors, new pathways?].

Bürger H.

Verh Dtsch Ges Pathol. 2006;90:124-7. German.

PMID:
17867588
[PubMed - indexed for MEDLINE]
6.

Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.

Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S, Lucini F, Ingvarsson S, Segatto O.

Oncogene. 2005 Jun 30;24(28):4540-8.

PMID:
15856022
[PubMed - indexed for MEDLINE]
7.

The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

Motoyama AB, Hynes NE, Lane HA.

Cancer Res. 2002 Jun 1;62(11):3151-8.

PMID:
12036928
[PubMed - indexed for MEDLINE]
Free Article
8.

ErbB receptors and signaling pathways in cancer.

Hynes NE, MacDonald G.

Curr Opin Cell Biol. 2009 Apr;21(2):177-84. doi: 10.1016/j.ceb.2008.12.010. Epub 2009 Feb 7. Review.

PMID:
19208461
[PubMed - indexed for MEDLINE]
9.

Prognostic value of ERBB family mRNA expression in breast carcinomas.

Bièche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R.

Int J Cancer. 2003 Sep 20;106(5):758-65.

PMID:
12866037
[PubMed - indexed for MEDLINE]
10.

Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.

Cancer Res. 2001 Dec 15;61(24):8887-95.

PMID:
11751413
[PubMed - indexed for MEDLINE]
Free Article
11.

Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.

Yuste L, Montero JC, Esparís-Ogando A, Pandiella A.

Cancer Res. 2005 Aug 1;65(15):6801-10.

PMID:
16061662
[PubMed - indexed for MEDLINE]
Free Article
12.

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.

Clin Cancer Res. 2006 Jul 1;12(13):4103-11.

PMID:
16818711
[PubMed - indexed for MEDLINE]
Free Article
13.

Progression and treatment of HER2-positive breast cancer.

Davoli A, Hocevar BA, Brown TL.

Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1. Epub 2009 Dec 20.

PMID:
20087739
[PubMed - indexed for MEDLINE]
14.
15.

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].

Dieras V, Vincent-Salomon A, Degeorges A, Beuzeboc P, Mignot L, de Cremoux P.

Bull Cancer. 2007 Mar;94(3):259-66. Review. French.

PMID:
17371768
[PubMed - indexed for MEDLINE]
16.

ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.

Ginestier C, Adélaïde J, Gonçalvès A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertucci F, Jacquemier J, Viens P, Birnbaum D.

Oncogene. 2007 Nov 1;26(50):7163-9. Epub 2007 May 21.

PMID:
17525746
[PubMed - indexed for MEDLINE]
17.

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases.

Stern DF.

Breast Cancer Res. 2000;2(3):176-83. Epub 2000 Mar 25. Review.

PMID:
11250707
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[Targeting ErbB receptors in breast cancer].

Fumoleau P, Campone M, Coudert B, Mayer F, Favier L, Ferrant E.

Bull Cancer. 2007;94(7 Suppl):F147-70. Review. French.

PMID:
17964992
[PubMed - indexed for MEDLINE]
19.

HER2 expression as a potential marker for response to therapy targeted to the EGFR.

Emlet DR, Schwartz R, Brown KA, Pollice AA, Smith CA, Shackney SE.

Br J Cancer. 2006 Apr 24;94(8):1144-53.

PMID:
16622439
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.

Singh LC, Chakraborty A, Mishra AK, Devi TR, Sugandhi N, Chintamani C, Bhatnagar D, Kapur S, Saxena S.

Med Oncol. 2012 Jun;29(2):539-46. doi: 10.1007/s12032-011-9952-6. Epub 2011 Apr 29.

PMID:
21528410
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk